M. Mercier

Clinical characteristics and prognostic factors of plasmablastic lymphoma patients: analysis of 135 patients from the LYSA group

Emmanuelle Tchernonog, P. Faurie, Paul Coppo et al. · Annals of Oncology · 2016 · 131 citations

Medicine, Hematology, Oncology +15

A prospective randomized trial of idarubicin vs daunorubicin in combination chemotherapy for acute myelogenous leukemia of the age group 55 to 75.

Josy Reiffers, F. Huguet, Anne Marie Stoppa et al. · PubMed · 1996 · 85 citations

Medicine, Oncology, Pharmacology +12

Reduced-intensity and non-myeloablative allogeneic stem cell transplantation from alternative HLA-mismatched donors for Hodgkin lymphoma: a study by the French Society of Bone Marrow Transplantation and Cellular Therapy

Jordan Gauthier, Luca Castagna, Federico Garnier et al. · Bone Marrow Transplantation · 2017 · 36 citations

Medicine, Hematology, Oncology +17

Reduced-intensity versus reduced-toxicity myeloablative fludarabine/busulfan-based conditioning regimens for allografted non-Hodgkin lymphoma adult patients: a retrospective study on behalf of the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire

Amandine Le Bourgeois, Myriam Labopin, Didier Blaise et al. · Annals of Oncology · 2017 · 16 citations · Full text

Medicine, Immunology, Oncology +12

Circulating Cd34+ cell count differentiates primary myelofibrosis from other Philadelphia-negative myeloproliferative neoplasms: a pragmatic study

Corentin Orvain, Damien Luque Paz, Irène Dobo et al. · Annals of Hematology · 2016 · 14 citations

Medicine, Hematology, Pathology +14